IRIS
CHIMENTI, MARIA SOLE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 36.485
EU - Europa 3.157
AS - Asia 2.015
SA - Sud America 17
OC - Oceania 15
AF - Africa 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 41.700
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 36.452
SG - Singapore 1.128
CN - Cina 623
IT - Italia 513
IE - Irlanda 487
DE - Germania 418
UA - Ucraina 404
FR - Francia 346
RU - Federazione Russa 325
GB - Regno Unito 189
FI - Finlandia 128
SE - Svezia 125
KR - Corea 112
PL - Polonia 100
BE - Belgio 47
IN - India 26
UZ - Uzbekistan 24
CA - Canada 23
JP - Giappone 19
IR - Iran 16
AU - Australia 14
AT - Austria 13
BR - Brasile 12
ES - Italia 12
HK - Hong Kong 11
MX - Messico 10
NL - Olanda 10
VN - Vietnam 9
TH - Thailandia 8
PK - Pakistan 7
RO - Romania 7
CH - Svizzera 6
KG - Kirghizistan 6
EG - Egitto 5
MY - Malesia 5
GR - Grecia 4
ID - Indonesia 4
IL - Israele 4
SI - Slovenia 4
TR - Turchia 4
BD - Bangladesh 3
CL - Cile 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
EU - Europa 3
HU - Ungheria 3
PH - Filippine 3
BG - Bulgaria 2
HR - Croazia 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
BJ - Benin 1
EC - Ecuador 1
KH - Cambogia 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 41.700
Salva come PNG Salva come JPEG
Città #
Wilmington 10.065
Woodbridge 9.292
Houston 9.115
Fairfield 1.283
Singapore 991
Ann Arbor 981
Chandler 799
Ashburn 611
Seattle 499
Cambridge 436
Dublin 422
Medford 328
Jacksonville 320
Santa Clara 247
New York 215
Beijing 162
Rome 159
Zhengzhou 159
Lawrence 155
Dearborn 132
Kraków 94
Moscow 84
San Diego 77
Redwood City 63
Menlo Park 59
Brussels 44
Nanjing 44
Seoul 41
Shanghai 40
Boardman 39
Milan 39
Chengdu 30
London 30
Norwalk 30
Los Angeles 28
Palo Alto 28
Hefei 26
Mülheim 25
Helsinki 24
Shenzhen 22
Falls Church 20
Lappeenranta 20
Mountain View 20
Council Bluffs 17
Esslingen am Neckar 17
San Mateo 17
Munich 16
Toronto 15
Augusta 13
Nuremberg 13
Verona 13
Bassano del Grappa 12
Guangzhou 12
Kunming 12
Bologna 10
Chicago 10
Del Norte 10
Jinan 10
Saint Petersburg 10
Ardabil 9
Center 9
Detroit 9
Kilburn 9
Las Vegas 9
Leawood 9
Wuhan 9
Hong Kong 8
Nürnberg 8
Phoenix 8
Scottsdale 8
Changsha 7
Dong Ket 7
Engelhard 7
Espoo 7
Padova 7
San Francisco 7
St. George 7
Hounslow 6
Mexico City 6
Nanchang 6
Peshawar 6
Redmond 6
Sydney 6
Indiana 5
Messina 5
Naples 5
Saint Louis 5
Shenyang 5
São Paulo 5
The Dalles 5
Tokyo 5
Williamsburg 5
Acton 4
Auburn Hills 4
Aversa 4
Bangkok 4
Brisbane 4
Durham 4
Fuzhou 4
Napoli 4
Totale 37.762
Salva come PNG Salva come JPEG
Nome #
Efficacy and safety of infliximab in psoriatic patients over the age of 65 501
Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases 488
Adalimumab for the treatment of severe psoriasis and psoriatic arthritis 465
Synovial fluid from patients with rheumatoid arthritis modulates monocyte cell-surface phenotype 458
Peripheral blood natural killer cells and mild thyroid abnormalities in women with reproductive failure 449
Complement and autoimmunity 444
Vasculitides and the Complement System: a Comprehensive Review 439
Expression of immunoglobulin-like transcript 4 as an inhibitory receptor in patients with psoriatic arthritis 434
Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: Is it possible after disease remission? 433
Serological markers associated with disease activity in patients with rheumatoid arthritis treated with rituximab 432
Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients 431
Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study 422
Self-reported adherence to a home-based exercise program among patients affected by psoriatic arthritis with minimal disease activity 420
Role of the complement system in rheumatoid arthritis and psoriatic arthritis: Relationship with anti-TNF inhibitors 419
C3 come indicatore di efficacia terapeutica in pazienti con artrite reumatoide in terapia con inibitori del TNFα 418
Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor 416
Apremilast for the treatment of psoriasis. 414
Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: The experience of two Italian integrated Dermatology/Rheumatology outpatient clinics 411
Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: A systematic review 411
Role of IL-23 in the pathogenesis of psoriasis: A novel potential therapeutic target? 411
Profile of certolizumab and its potential in the treatment of psoriatic arthritis 409
Evidence of IL-17 producing innate lymphoid cells in peripheral blood from patients with enteropathic spondyloarthritis 409
Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients 408
Emergence of antinuclear antibodies in psoriatic patients treated with infliximab: personal experience and literature review 408
Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response 407
The significance of the development of antinuclear antibodies during infliximab treatment 404
Autoantibodies in inflammatory arthritis 400
Two HLA-B27 alleles differently associated with spondylarthritis, B*2709 and B*2705, display similar intracellular trafficking and oligomer formation 398
Complement system in rheumatoid arthritis: evidence of correlation with disease activity but not with anti-citrullinated protein antibodies 398
Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study 398
Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics 398
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis 394
Occurrence of localized scleroderma morphea in a patient with rheumatoid arthritis treated with etanercept 393
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy 390
Resolution of idiopathic recurrent pericarditis in a psoriatic arthritis patient treated with etanercept 387
Sistema complementare e artrite reumatoide: Correlazioni con autoanticorpi, caratteristiche cliniche e di laboratorio e farmaci anti-TNF α 387
Continuous treatment of plaque-type psoriasis with etanercept: An observational long-term experience 387
Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis 387
Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. 384
The autoimmune side of hereditary angioedema: Insights on the pathogenesis 384
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 383
Diagnosis of pigmented skin lesions by dermoscopy: web-based training improves diagnostic performance of non-experts 383
Alteration of antigen-independent immunologic synapse formation between dendritic cells from HLA-B27-transgenic rats and CD4+ T cells: selective impairment of costimulatory molecule engagement by mature HLA-B27 383
The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies 383
Type I lamellar ichthyosis improved by tazarotene 0.1% gel 383
IL-21 in the pathogenesis and treatment of skin diseases 382
Auto-reactions, autoimmunity and psoriatic arthritis 378
Discontinuation of anti-TNFα therapy due to remission in rheumatoid arthritis: A retrospective study 375
Complement system in psoriatic arthritis: a useful marker and a potential therapeutic target of anti-tnf-alpha treatment 372
Metabolic profiling of human CD4+ cells following treatment with methotrexate and anti-TNF-α infliximab 372
The interplay between inflammation and metabolism in rheumatoid arthritis 371
Small-medium vessel vasculitides: Is the complement system a potential forgotten target? 371
S100A8/A9 in psoriatic plaques from patients with psoriatic arthritis 369
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers 367
Skin reaction associated with chrysotherapy: an unusual case 365
Insights on the role of physical activity in patients with rheumatoid arthritis 364
Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways 362
Downregulation of immunoglobulin-like transcript-4 (ILT4) in patients with psoriatic arthritis 361
Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse 358
The significance the role of anti-tnf-alpha effects on endothelial dysfunction in psoriasic arthritis 357
A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors 357
Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment 355
Innate Immune System at the Maternal–Fetal Interface: Mechanisms of Disease and Targets of Therapy in Pregnancy Syndromes 355
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Design, development, and use in therapy 350
Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate 349
The pathogenic role of the complement system in rheumatoid arthritis and its relationship with TNFα inhibitors 343
Small molecule therapy for managing moderate to severe psoriatic arthritis 343
Morphometric analysis of capillaroscopic images during psoriatic arthritis: comparison with rheumatoid artrhitis 341
Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence 338
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy 337
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 333
Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015) 332
From patients’ needs to treatment outcomes in psoriasis: Results from the ‘pSORRIDI’ experience 330
Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: a role for scintigraphy with 99mTc-infliximab 324
How to diagnose spondyloarthritis early? Accuracy of peripheral enthesitis detection by power Doppler ultrasonography 318
Natural killer and b cells in patients with rheumatoid arthritis and psoriatic arthritis treated with etanercept 317
Tofacitinib for the treatment of moderate-to-severe psoriasis 317
The complex interplay between rheumatoid arthritis and atopy: Focus on anti-TNFα treatment 316
Ultrasound assessment of enthesis thickness in psoriasis and psoriatic arthritis: A cross-sectional study 313
Systemic sclerosis: Exploring the potential interplay between thyroid disorders and pregnancy outcome in an Italian cohort 304
High-dose Intravenous Immunoglobulin for Severe Drug Reactions: Efficacy in Toxic Epidermal Necrolysis 300
Effects of abatacept on T-lymphocyte sub-populations and immunoglobulins in patients affected by rheumatoid arthritis 298
Histopathology of the skin in rheumatic diseases 298
Treatment of Hailey-Hailey disease with topical calcitriol 297
Factors predicting 2 years of remission and low disease activity in rheumatoid arthritis patients treated with TNF-inhibitors 293
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 293
Hereditary angioedema and autoimmunity 290
null 287
Radiologically significant joint improvement in a patient affected by psoriatic arthritis treated with adalimumab 281
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 280
Evidence for the detection of subclinical retinal involvement in systemic Lupus erythematosus and Sjögren syndrome: a potential association with therapies 277
Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: New biomarkers in PsA 277
Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. 272
Challenges in the treatment of Rheumatoid Arthritis 263
Interaction between microbiome and host genetics in psoriatic arthritis 236
Complement, infection, and autoimmunity 228
Use of synthetic and biological DMARDs in patients with enteropathic spondyloarthritis: a combined gastro-rheumatological approach 226
Successful treatment of psoriatic crumbly nails with ustekinumab 212
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 201
Enteropathic spondyloarthritis: Results from a large nationwide database analysis 188
Totale 36.054
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.101
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.101
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207.832 0 0 0 0 848 1.295 977 1.042 1.069 1.066 758 777
2020/20218.098 778 962 925 956 894 873 1.029 839 307 210 260 65
2021/20221.711 95 197 160 89 50 86 86 87 97 124 173 467
2022/20232.052 210 177 88 256 188 461 171 135 182 42 104 38
2023/20241.084 95 30 36 28 132 272 43 147 58 19 54 170
2024/20252.398 184 1.211 636 312 55 0 0 0 0 0 0 0
Totale 42.590